SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Scienture Holdings, Inc. announced Q1 2026 financial results showing a significant 449% increase in revenue year-over-year to $56 thousand and a substantial gross margin expansion to 95.6%, driven primarily by increased sales of ArbliTM, an innovative liquid formulation of losartan. The company also secured important patents for ArbliTM and REZENOP…